首页> 美国卫生研究院文献>PLoS Clinical Trials >HIV drug resistance in HIV positive individuals under antiretroviral treatment in Shandong Province, China
【2h】

HIV drug resistance in HIV positive individuals under antiretroviral treatment in Shandong Province, China

机译:中国山东省接受抗逆转录病毒治疗的HIV阳性个体的HIV耐药性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

The efficacy of antiretroviral drugs is limited by the development of drug resistance. Therefore, it is important to examine HIV drug resistance following the nationwide implementation of drug resistance testing in China since 2009. We conducted drug resistance testing in patients who were already on or new to HIV antiretroviral therapy (ART) in Shandong Province, China, from 2011 to 2013, and grouped them based on the presence or absence of drug resistance to determine the effects of age, gender, ethnicity, marital status, educational level, route of transmission and treatment status on drug resistance. We then examined levels of drug resistance the following year. The drug resistance rates of HIV patients on ART in Shandong from 2011 to 2013 were 3.45% (21/608), 3.38% (31/916), and 4.29% (54/1259), per year, respectively. M184V was the most frequently found point mutation, conferring resistance to the nucleoside reverse transcriptase inhibitor, while Y181C, G190A, K103N and V179D/E/F were the most frequent point mutations conferring resistance to the non-nucleoside reverse transcriptase inhibitor. In addition, the protease inhibitor drug resistance mutations I54V and V82A were identified for the first time in Shandong Province. Primary resistance accounts for 20% of the impact factors for drug resistance. Furthermore, it was found that educational level and treatment regimen were high-risk factors for drug resistance in 2011 (P<0.05), while treatment regimen was a high risk factor for drug resistance in 2012 and 2013 (P<0.05). Among the 106 drug-resistant patients, 77 received immediate adjustment of treatment regimen following testing, and 69 (89.6%) showed a reduction in drug resistance the following year. HIV drug resistance has a low prevalence in Shandong Province. However, patients on second line ART regimens and those with low educational level need continuous monitoring. Active drug resistance testing can effectively prevent the development of drug resistance.
机译:抗逆转录病毒药物的疗效受到耐药性发展的限制。因此,自2009年以来在中国全国范围内实施抗药性检测之后,对HIV的抗药性进行检测非常重要。我们对来自中国山东省的HIV抗逆转录病毒疗法(ART)的新手或新患者进行了抗药性测试2011年至2013年,并根据是否存在耐药性将其分组,以确定年龄,性别,种族,婚姻状况,教育水平,传播途径和治疗状况对耐药性的影响。然后,我们在第二年检查了耐药性水平。 2011年至2013年,山东省抗艾滋病毒/艾滋病患者的耐药率分别为3.45%(21/608),3.38%(31/916)和4.29%(54/1259)。 M184V是最常见的点突变,赋予了对核苷逆转录酶抑制剂的抗性,而Y181C,G190A,K103N和V179D / E / F是最常见的点突变,赋予了对非核苷逆转录酶抑制剂的抗性。此外,在山东省首次发现了蛋白酶抑制剂耐药性突变I54V和V82A。原发性耐药占耐药性影响因素的20%。此外,发现受教育程度和治疗方案是2011年耐药性的高风险因素(P <0.05),而治疗方案是2012年和2013年耐药性的高风险因素(P <0.05)。在106名耐药患者中,有77名在测试后立即接受了治疗方案的调整,而次年69名(89.6%)的耐药性有所降低。 HIV耐药性在山东省的患病率较低。但是,采用第二线抗逆转录病毒疗法的患者和文化程度较低的患者需要持续监测。主动的耐药性测试可以有效防止耐药性的发展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号